🇺🇸 FDA

Drug profile · INN

asparaginase erwinia chrysanthemi (recombinant)-rywn

RYLAZE

approved
US status
approved
Patents linked
0
News articles
0

Quick answer

asparaginase erwinia chrysanthemi (recombinant)-rywn (RYLAZE) is an FDA-listed pharmaceutical active ingredient. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN asparaginase erwinia chrysanthemi (recombinant)-rywn
Brand RYLAZE
Route INTRAMUSCULAR
Formulation INJECTABLE
Originator Jazz Pharmaceuticals Ireland Limited

Frequently asked questions

What is asparaginase erwinia chrysanthemi (recombinant)-rywn?

asparaginase erwinia chrysanthemi (recombinant)-rywn (RYLAZE) is an FDA-listed pharmaceutical active ingredient. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for asparaginase erwinia chrysanthemi (recombinant)-rywn?

RYLAZE is a marketed brand name for asparaginase erwinia chrysanthemi (recombinant)-rywn. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of asparaginase erwinia chrysanthemi (recombinant)-rywn?

asparaginase erwinia chrysanthemi (recombinant)-rywn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.